Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary

Overview of Results

For the second quarter of the fiscal year ending March 2027, consolidated net sales were 15,941 million yen, an increase of 9.7% year-over-year. Operating income improved to 748 million yen, while ordinary income declined year-over-year due to factors including foreign exchange impacts. Interim net income attributable to owners of the parent increased significantly due to special gains and other factors. By segment, Japan, Asia, and Europe made solid contributions, and the Americas recorded revenue growth supported by continued medical device demand, although some foreign exchange effects were observed. There is no change to the full-year forecast, and the company maintains its current policy on year-end dividends.

Outlook and Capital Position

The full-year outlook remains at the previously announced level. Cash and cash equivalents have increased, and the equity ratio is maintained at 32.8%. Foreign exchange volatility at overseas sites remains a point of attention, but consolidated cash flow trends are stable. Growth drivers by segment include Japanese automotive and precision equipment, medical devices in the Americas, recovery in European aircraft demand, and capturing automotive and medical device demand in Asia.